# Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

> **NCT00021047** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)**

## Conditions studied

- Esophageal Cancer
- Extrahepatic Bile Duct Cancer
- Gastric Cancer
- Head and Neck Cancer
- Liver Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** capecitabine
- **DRUG:** carboplatin
- **DRUG:** epirubicin hydrochloride

## Key facts

- **NCT ID:** NCT00021047
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** — (—)
- **Last updated:** 2012-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021047, "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00021047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*